Braidwell LP Invests $9.09 Million in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Braidwell LP acquired a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 483,300 shares of the company’s stock, valued at approximately $9,091,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Verition Fund Management LLC purchased a new stake in Jasper Therapeutics in the 3rd quarter worth approximately $477,000. Ally Bridge Group NY LLC lifted its holdings in shares of Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after buying an additional 3,873 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the period. Finally, FMR LLC purchased a new stake in Jasper Therapeutics during the 3rd quarter worth $722,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

JSPR stock opened at $23.24 on Friday. The firm has a market cap of $348.60 million, a price-to-earnings ratio of -4.90 and a beta of 2.19. Jasper Therapeutics, Inc. has a 1-year low of $4.00 and a 1-year high of $31.01. The firm has a fifty day moving average price of $20.26 and a two-hundred day moving average price of $20.90.

Analyst Ratings Changes

JSPR has been the topic of several recent analyst reports. Evercore ISI reiterated an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Thursday, October 24th. Finally, Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $74.86.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.